177 research outputs found
TG4010 immunotherapy: a novel weapon against advanced non-small cell lung cancer?
Over 1.5 million new cases of non-small cell lung cancer
(NSCLC), a highly aggressive disease, are registered
worldwide every year (1). Until the 1980s, treatment
generally yielded poor outcomes (2), and prognosis was
only good for early stages of operable disease. However,
advances in targeted molecular therapy since 2005 have
brought new hope to patients with advanced NSCLC,
especially those harboring the epidermal growth factor receptor
(EGFR) mutation in exons 18, 19 and 21 (3). As a result, the
median overall survival (OS) of a small group of patients with
advanced NSCLC increased from 10 to 18–36 months (2)
Personalizing medicine for metastatic colorectal cancer: Current developments
Metastatic colorectal cancer (mCRC) is still one of the tumor types with the highest incidence and mortality. In 2012, colorectal cancer was the second most prevalence cancer among males (9%) and the third among females (8%). In this disease, early diagnosis is important to improve treatment outcomes. However, at the time of diagnosis, about one quarter of patients already have metastases, and overall survival of these patients at 5-years survival is very low. Because of these poor statistics, the development of new drugs against specific targets, including the pathway of angiogenesis, has witnessed a remarkable increase. So, targets therapies through epidermal growth factor and its receptor and also KRAS pathways modulation acquired a main role whether in association with standard chemotherapy and radiotherapy. With the current knowledge in the field of molecular biology, including genetic mutations and polymorphisms, we know better why patients respond so differently to the same treatments. So, in the future we can develop increasingly personalized treatments to the patient and not the disease. This review aims to summarize some molecular pathways and their relation to tumor growth, as well as novel targeted developing drugs and recently approved for mCRC. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.info:eu-repo/semantics/publishedVersio
Potential role of immunotherapy in advanced non-small-cell lung cancer
Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib, erlotinib, and afatinib) or with anaplastic lymphoma kinase inhibitors (eg, crizotinib and ceritinib). As a result, anti-PD- 1/PD-L1 and CTLA-4 inhibitors may play a novel role in the improvement of outcomes in a metastatic setting. The regulation of immune surveillance, immunoediting, and immunoescape mechanisms may play an interesting role in this regard either alone or in combination with current drugs. Here, we discuss advances in immunotherapy for the treatment of metastatic non-small-cell lung cancer as well as future perspectives within this framework.Pierre Fabr
Insights into angiogenesis in non-small cell lung cancer : molecular mechanisms, polymorphic genes, and targeted therapies
We would like to thank Dr. Miguel Nunes from Department of Informatic of Faculty of Medicine of the University of Porto, Porto, Portugal, for his help in technical support,
and Prof. Henrique Queiroga, Department of Pneumology of Faculty of Medicine of the University of Porto, Porto, Portugal, for his critical contribution in this manuscript reviewLung cancer is a highly prevalent disease worldwide. Currently, there are more than 150 million patients with lung cancer in the world, with more than 1 million new cases diagnosed per year. Tumoral angiogenesis is an important hallmark of this disease, but despite being extensively studied, the complete angiogenic mechanisms are not fully elucidated. Recent studies have reported a correlation between pharmacological inhibition of these angiogenic mechanisms and improvement of overall survival in lung cancer patients, mainly for those in advanced stages. The family of vascular endothelial growth factor (VEGF) proteins has critical roles in tumoral angiogenesis. An interaction between VEGF-A and VEGF receptor 2 (VEGFR-2) is the main pathway of activation and maintenance of angiogenesis. In tumors, this process is intimately correlative with progression and metastasis. Some studies suggested that serum levels of VEGF are higher in patients with lung cancer, especially in some types of non-small cell lung cancer (NSCLC). Other studies revealed that genetic polymorphisms of VEGF correlate with susceptibility, prognosis, and therapeutic response of some patients with NSCLC. This paper aims to review the impact of angiogenesis, especially on VEGF pathways, in NSCLC, and highlights the relevance of known and new patents disclosed of anti-angiogenic therapies in these patients
Hemophagocytic Syndrome Associated with Hodgkin's Lymphoma First Presenting as Fever and Pancytopenia
Background. Hemophagocytic syndrome (HPS) is characterized by a hyperinflammatory reaction followed by alteration in cytotoxic function of Th1 lymphocytes and natural killer cells. We report a rare case of a patient that presented with fever and pancytopenia due to HPS associated with Hodgkin's lymphoma (HL). Case Report. A 69-year-old Caucasian woman was admitted presenting with complaints of fever, seizures, and low back pain that had lasted for two weeks. Laboratorial data showed pancytopenia. Bone marrow biopsy revealed infiltration by Reed-Sternberg cells and hemophagocytosis signs. Imaging studies showed mediastinal lymph nodes (stage IV B). She had been treated with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) followed by a good response. Conclusion. HPS associated with HL is a very rare and lethal disease, with mortality rates of about 15% to 60%. The prompt diagnosis of the underlying lymphoma may be an important strategy for optimizing the clinical approach and outcome
An estimate of the economic impact of immunotherapy relative to PD-L1 expression in Brazil - An update with brazilian costs
Delivering high quality cancer care at an affordable cost is one of the main challenges for health care professionals and policy makers, especially in lowand middle-income countries. The objective of our study is to assess the economic impact of nivolumab and
pembrolizumab with and without the use of PD-L1 as a biomarker in Brazil.info:eu-repo/semantics/publishedVersio
Angiogenesis and apatinib: a new hope for patients with advanced gastric cancer?
Amgen; Pierre Fabreinfo:eu-repo/semantics/publishedVersio
Loci identificados através de estudo de associação genômica ampla e risco de câncer do pulmão: existe algo mais?
Letter to editor.(undefined
Anti-EGFR monoclonal antibodies plus chemotherapy in the first-line treatment of advanced NSCLC: a meta-analysis
- …